Results 31 to 40 of about 3,635,661 (309)
Informed consent and placebo effects: a content analysis of information leaflets to identify what clinical trial participants are told about placebos [PDF]
, 2012 BackgroundPlacebo groups are used in randomised clinical trials (RCTs) to control for placebo effects, which can be large. Participants in trials can misunderstand written information particularly regarding technical aspects of trial design such as ...
Adams, Alison E.M. +3 more
core +5 more sources
Advancing Pediatric Antibacterial Drug Development: A Critical Need to Reinvent our Approach. [PDF]
, 2019 The Clinical Trials Transformation Initiative convened with several groups in the pediatric antibacterial drug development community with the goal of identifying challenges and recommending ways to improve current practice.
Bradley, John +3 more
core +1 more source
Active Clinical Trials for Personalized Medicine
, 2015 Individualized treatment rules (ITRs) tailor treatments according to individual patient characteristics. They can significantly improve patient care and are thus becoming increasingly popular.
Cheng, Guang +2 more
core +2 more sources
A working model for cytoplasmic assembly of H/ACA snoRNPs
FEBS Letters, EarlyView.Dyskerin is the component of nuclear H/ACA ribonucleoproteins (RNPs) endowed with pseudouridine synthase catalytic activity. Two isoforms of human dyskerin have been characterized: the abundant Iso1, mainly nuclear, and the shorter Iso3, mainly cytoplasmic but occasionally imported into nuclei.
Alberto Angrisani, Maria Furia
wiley +1 more source
Review of precision cancer medicine: Evolution of the treatment paradigm. [PDF]
, 2020 In recent years, biotechnological breakthroughs have led to identification of complex and unique biologic features associated with carcinogenesis. Tumor and cell-free DNA profiling, immune markers, and proteomic and RNA analyses are used to identify ...
Fountzilas, Elena +3 more
core +1 more source
Imeglimin attenuates liver fibrosis by inhibiting vesicular ATP release from hepatic stellate cells
FEBS Letters, EarlyView.Imeglimin, at clinically relevant concentrations, inhibits vesicular ATP accumulation and release from hepatic stellate cells, thereby attenuating purinergic signaling and reducing fibrogenic activation. This mechanism reveals a newly identified antifibrotic action of imeglimin beyond glycemic control.
Seiji Nomura +8 more
wiley +1 more source
Trials, 2017 Background Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal residual disease (MRD) negativity in CLL is an independent predictor of survival even with a variety of different treatment approaches and regardless of ...
Jamie B. Oughton +10 more
doaj +1 more source
Paying clinicians to join clinical trials : a review of guidelines and interview study of trialists [PDF]
, 2009 Background: The motivations of clinicians to participate in clinical trials have been little studied. This project explored the potential role of payment for participation in publicly funded clinical trials in the UK.
Association of British Pharmaceutical Industries +23 more
core +3 more sources
RAD50 missense variants differentially affect the DNA damage response and mitotic progression
FEBS Letters, EarlyView.RAD50 incorporates into the MRN complex and initiates the DNA damage response. Furthermore, RAD50 promotes mitotic progression. RAD50 missense variants capable of forming an MRN complex supported the DNA damage response and mitotic features to different extents in complementation experiments, indicating these functions are separable and might impact ...
Hanna Redeker +9 more
wiley +1 more source